We report a case of bilateral macular edema (ME) within 10 days of starting fingolimod 0.5 mg therapy in a patient with Multiple Sclerosis (MS). The complication resolved without treatment as demonstrated by sequential Optical Coherence Tomography (OCT). Fingolimod is a sphingosine-1-phosphate receptor modulator that reduces lymphocyte presence in the CNS. In pivotal trials, ME, a known complication of fingolimod, typically occurred unilaterally with onset at approximately 3 months. A 60 y/o AA female, diagnosed with MS in 1977, started oral fingolimod treatment on 05/31/2011. Baseline screening with OCT and ophthalmology evaluation showed no ME. On 06/10, she developed bilateral blurry vision and discontinued fingolimod. On 06/27, OCT revealed severe bilateral ME. Later OCT exams showed a progressive decrease in Central Foveal Thickness (CFT) and Macular Volume (MV), without specific treatment other than discontinuation of fingolimod. On 7/27, CFT, MV, and Visual Acuity (VA) were similar to baseline. This is the first reported case of bilateral, early onset ME following fingolimod treatment at the current FDA-approved dose of 0.5 mg. Diabetes, a known risk factor for ME, may have contributed to her early, bilateral involvement. Our case provides further support for earlier OCT, in conjunction with ophthalmic examinations, for at-risk patients on fingolimod, and suggests that cessation of fingolimod may be associated with resolution of ME.
Abbreviations:OCT (optical coherence tomography), ME (macular edema), CFT (central foveal thickness), MV (macular volume), VA (visual acuity), S1PR (sphingosine-1-phosphate receptor)
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
FDA and CDER. Peripheral and central nervous system drugs advisory committee meeting: Fingolimod (NDA 22–527) background package; 2010.
- The immune modulator FTY720 targets sphingosine 1-phosphate receptors.Journal of Biological Chemistry. 2002; 277: 21453-21457
- Fingolimod-associated macular edema: incidence, detection, and management.Neurology. 2012; 78: 672-680
- Macular edema.Survey of Ophthalmology. 2004; 49.5: 470-490
- Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis.Neuron. 2003; : 38685-38688
Published online: January 18, 2013
Accepted: November 23, 2012
Received in revised form: November 2, 2012
Received: July 9, 2012
© 2012 Elsevier B.V. Published by Elsevier Inc. All rights reserved.